Cargando…
Uptake of the lateral flow urine LAM test in Europe and Central Asia
INTRODUCTION: Since 2015 (updated in 2019), the WHO has recommended to include the commercial lateral flow urine lipoarabinomannan TB test (LF-LAM), AlereLAM, in the diagnostic toolkit for severely ill people living with HIV. METHODS: To assess the current use and barriers to the implementation of t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Union Against Tuberculosis and Lung Disease
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423022/ https://www.ncbi.nlm.nih.gov/pubmed/35996279 http://dx.doi.org/10.5588/ijtld.21.0656 |
_version_ | 1784777937422123008 |
---|---|
author | Kraef, C. Yedilbayev, A. Seguy, N. Bentzon, A. Podlekareva, D. Cirillo, D. M. van der Werf, M. J. Kirk, O. |
author_facet | Kraef, C. Yedilbayev, A. Seguy, N. Bentzon, A. Podlekareva, D. Cirillo, D. M. van der Werf, M. J. Kirk, O. |
author_sort | Kraef, C. |
collection | PubMed |
description | INTRODUCTION: Since 2015 (updated in 2019), the WHO has recommended to include the commercial lateral flow urine lipoarabinomannan TB test (LF-LAM), AlereLAM, in the diagnostic toolkit for severely ill people living with HIV. METHODS: To assess the current use and barriers to the implementation of the test, we conducted an electronic survey among national focal points and managers of TB and HIV programmes in the 53 Member States of the WHO European Region and a European network of clinicians working in TB and HIV medicine. RESULTS: In all, 45 individual responses (37 countries) were received from programme managers and focal points and 17 responses (14 countries) from clinicians. Only eight countries reported adopting LF-LAM policies, with only four currently using the AlereLAM (Armenia, Belarus, Ukraine and Uzbekistan). The most commonly reported barriers to implementing the test were the small number of eligible patients (with HIV-TB co-infections), the test not being included in the TB or HIV programme’s mandate and lack of budget allocation. CONCLUSION: Consistent with findings from high TB burden countries in Africa and Asia, the survey demonstrated that uptake of AlereLAM is almost non-existent. Addressing the identified barriers and the intrinsic limitations of the test could help to increase the use of the test. |
format | Online Article Text |
id | pubmed-9423022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | International Union Against Tuberculosis and Lung Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-94230222022-09-05 Uptake of the lateral flow urine LAM test in Europe and Central Asia Kraef, C. Yedilbayev, A. Seguy, N. Bentzon, A. Podlekareva, D. Cirillo, D. M. van der Werf, M. J. Kirk, O. Int J Tuberc Lung Dis Original Articles INTRODUCTION: Since 2015 (updated in 2019), the WHO has recommended to include the commercial lateral flow urine lipoarabinomannan TB test (LF-LAM), AlereLAM, in the diagnostic toolkit for severely ill people living with HIV. METHODS: To assess the current use and barriers to the implementation of the test, we conducted an electronic survey among national focal points and managers of TB and HIV programmes in the 53 Member States of the WHO European Region and a European network of clinicians working in TB and HIV medicine. RESULTS: In all, 45 individual responses (37 countries) were received from programme managers and focal points and 17 responses (14 countries) from clinicians. Only eight countries reported adopting LF-LAM policies, with only four currently using the AlereLAM (Armenia, Belarus, Ukraine and Uzbekistan). The most commonly reported barriers to implementing the test were the small number of eligible patients (with HIV-TB co-infections), the test not being included in the TB or HIV programme’s mandate and lack of budget allocation. CONCLUSION: Consistent with findings from high TB burden countries in Africa and Asia, the survey demonstrated that uptake of AlereLAM is almost non-existent. Addressing the identified barriers and the intrinsic limitations of the test could help to increase the use of the test. International Union Against Tuberculosis and Lung Disease 2022-09 2022-09-01 /pmc/articles/PMC9423022/ /pubmed/35996279 http://dx.doi.org/10.5588/ijtld.21.0656 Text en © 2022 The Union https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Original Articles Kraef, C. Yedilbayev, A. Seguy, N. Bentzon, A. Podlekareva, D. Cirillo, D. M. van der Werf, M. J. Kirk, O. Uptake of the lateral flow urine LAM test in Europe and Central Asia |
title | Uptake of the lateral flow urine LAM test in Europe and Central Asia |
title_full | Uptake of the lateral flow urine LAM test in Europe and Central Asia |
title_fullStr | Uptake of the lateral flow urine LAM test in Europe and Central Asia |
title_full_unstemmed | Uptake of the lateral flow urine LAM test in Europe and Central Asia |
title_short | Uptake of the lateral flow urine LAM test in Europe and Central Asia |
title_sort | uptake of the lateral flow urine lam test in europe and central asia |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423022/ https://www.ncbi.nlm.nih.gov/pubmed/35996279 http://dx.doi.org/10.5588/ijtld.21.0656 |
work_keys_str_mv | AT kraefc uptakeofthelateralflowurinelamtestineuropeandcentralasia AT yedilbayeva uptakeofthelateralflowurinelamtestineuropeandcentralasia AT seguyn uptakeofthelateralflowurinelamtestineuropeandcentralasia AT bentzona uptakeofthelateralflowurinelamtestineuropeandcentralasia AT podlekarevad uptakeofthelateralflowurinelamtestineuropeandcentralasia AT cirillodm uptakeofthelateralflowurinelamtestineuropeandcentralasia AT vanderwerfmj uptakeofthelateralflowurinelamtestineuropeandcentralasia AT kirko uptakeofthelateralflowurinelamtestineuropeandcentralasia |